XML 24 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 188 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Mar. 31, 2012
Revenues:      
Collaboration and research and development revenue     $ 3,100
Product revenue 161 192 3,182
Grant revenue     3,648
Total revenues 161 192 9,930
Operating expenses:      
Cost of goods sold 94 106 1,846
Research and development 1,347 3,080 187,146
Selling, general and administrative 1,996 1,806 91,483
Goodwill and intangible impairment     7,934
Restructuring costs     2,634
Total operating expenses 3,437 4,992 291,043
Operating loss (3,276) (4,800) (281,113)
Other income (expense):      
Costs associated with aborted 2004 IPO     (3,550)
Payment under guarantee     (1,652)
Change in valuation of Economic Rights (56)   (56)
Change in valuation of other liabilities measured at fair value 42 78 6,413
Foreign exchange (losses)/gains 114 (68) (4,259)
Interest income 6 11 13,731
Interest expense     (4,677)
Other income 47   47
Total other income (expense) 153 21 5,997
Loss before taxes (3,123) (4,779) (275,116)
Income tax benefit 168 191 18,612
Net loss (2,955) (4,588) (256,504)
Dividends on preferred ordinary shares     (38,123)
Deemed dividend on convertible exchangeable preferred shares     (3,515)
Dividend on convertible exchangeable preferred shares (182) (182) (3,839)
Net loss applicable to common shareholders $ (3,137) $ (4,770) $ (301,981)
Net loss per share - Basic and diluted (in dollars per share) $ (0.06) $ (0.10)  
Weighted average common shares outstanding (in shares) 54,761,620 46,572,180